Table 2.
Human killer DCs divided into major subsetsc
| Subset of DC | Stimulation | Target | E:T ratio | Killing mechanism | Refs |
|---|---|---|---|---|---|
| mDCs | |||||
| CD11c+ blood mDCs | IFNα, IFNγ | Jurkat OVCAR3 PC-3 WM793 |
50:1 | TRAIL | [40] |
| CD11c+ blood mDCs | IFNγ, IL-15, LPS |
MCF-7 HBL-100 (breast cancer) MDA-MB-231 (breast cancer) MDA-MB-415 (breast cancer) |
10:1 | ND | [88] |
| CD11c+ mDCs | IMQ | K562 | 25:1 | Perforin/granzyme B | [44] |
| CD1c+ mDCs (CHC patients)b | Unstimulated | K562 U937 Jurkat |
50:1 | TRAIL | [42] |
| CD11c+ blood mDCs | IL-15 | Human aortic endothelial cells Porcine aortic endothelial cells |
10:1 | Granzyme Ba /caspase 8 |
[45] |
| Blood mDCs BDCA-1+ |
LPS | Allogeneic healthy CD4+ T cells Autologous CD4+ T cells |
4:1 | FAS-L PD-L2 Contact dependent |
[32] |
| pDCs | |||||
| pDC cell line GEN2.2 Blood pDCs → |
Influenza virus, Type I IFNs Influenza virus |
A549 (epithelial cancer) A549 |
25:1 15:1 |
TRAILa TRAIL |
[49] |
| Blood pDCs | IMQ | Jurkat | 25:1 | TRAIL | [44] |
| Blood pDCs | HIV-1 | SupT1 (CD4+ T cell line) | 20:1 | TRAILa | [56] |
| Blood pDCs | HIV-1 | CD4+ T cells (HIV-1 viremic patients) | 10:1 | TRAIL IFNα |
[89] |
| Blood pDCs | IL-3/CD40L → CpG → |
K562 K562 1806 (breast cancer) Colo829 (melanoma) |
100:1 | Contact dependent ND |
[52] |
| Blood pDCs | Flu CpG |
Jurkat J32 | Culture Sup |
TRAIL | [90] |
| Blood pDCs | HTLV-1 | DR5+ T cells | 1:2 | TRAIL | [55] |
| Blood pDCs | HIV | HIV-infected Sup-T1 cell line | 10:1 | TRAIL | [58] |
| Blood pDCs | IL-3/IL-10 | T cells | 1:250 | Granzyme B | [54] |
| Blood pDCs | IL-3 | K562 | 10:1 | Granzyme B /Caspase |
[53] |
| Blood pDCs | CpG | H9 (CD4+ T cell line) | 2:1 | TRAILa | [57] |
| Blood pDCs | IMQ CpG IFNα |
Jurkat WM793 SKMel2 (melanoma) Jurkat Jurkat WM793 SKMel2 |
20:1 | TRAIL | [51] |
| Blood pDCs | IL-3 → R848 → FSME → |
K562 K562 K562 Daudi (lymphatic cancer) |
20:1 | ND ND Contact dependent |
[50] |
a
Partially dependent, other mechanisms (shown when possible) may be involved.
b
Chronic hepatitis C patients.
c
Abbreviation: IMQ, imiquimod.